Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Biotage

BATS-CHIXE:BIOTS
Snowflake Description

Solid track record with excellent balance sheet and pays a dividend.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BIOTS
BATS-CHIXE
SEK6B
Market Cap
  1. Home
  2. GB
  3. Pharmaceuticals & Biotech
Company description

Biotage AB (publ), a life science company, provides solutions, knowledge, and experience in the areas of organic and analytical chemistry, as well as for industrial applications in the United States, Europe, Japan, China, and internationally. The last earnings update was 53 days ago. More info.


Add to Portfolio Compare Print
  • Biotage has significant price volatility in the past 3 months.
BIOTS Share Price and Events
7 Day Returns
11.4%
BATS-CHIXE:BIOTS
19.9%
GB Life Sciences
10%
GB Market
1 Year Returns
-22.4%
BATS-CHIXE:BIOTS
-15.8%
GB Life Sciences
-23%
GB Market
BIOTS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Biotage (BIOTS) 11.4% -12.9% -20.4% -22.4% 135.7% -
GB Life Sciences 19.9% -20.4% -32% -15.8% -16.1% -24.9%
GB Market 10% -17.6% -27.3% -23% -24.2% -21.8%
1 Year Return vs Industry and Market
  • BIOTS underperformed the Life Sciences industry which returned -15.8% over the past year.
  • BIOTS matched the United Kingdom of Great Britain and Northern Ireland Market (-23%) over the past year.
Price Volatility
BIOTS
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Biotage undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Biotage to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Biotage.

BATS-CHIXE:BIOTS Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.2%
Perpetual Growth Rate 10-Year GB Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BATS-CHIXE:BIOTS
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GB Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 5.4%
Life Sciences Unlevered Beta Simply Wall St/ S&P Global 1.03
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.033 (1 + (1- 22%) (2.62%))
1.036
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.04
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.53% + (1.036 * 5.44%)
6.17%

Discounted Cash Flow Calculation for BATS-CHIXE:BIOTS using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Biotage is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

BATS-CHIXE:BIOTS DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (SEK, Millions) Source Present Value
Discounted (@ 6.17%)
2020 179.00 Analyst x1 168.60
2021 220.00 Analyst x1 195.18
2022 248.00 Analyst x1 207.25
2023 267.52 Est @ 7.87% 210.57
2024 282.68 Est @ 5.67% 209.58
2025 294.34 Est @ 4.13% 205.55
2026 303.31 Est @ 3.05% 199.51
2027 310.27 Est @ 2.29% 192.23
2028 315.74 Est @ 1.76% 184.26
2029 320.14 Est @ 1.39% 175.98
Present value of next 10 years cash flows SEK1,948.00
BATS-CHIXE:BIOTS DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= SEK320.14 × (1 + 0.53%) ÷ (6.17% – 0.53%)
SEK5,709.63
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= SEK5,709.63 ÷ (1 + 6.17%)10
SEK3,138.52
BATS-CHIXE:BIOTS Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= SEK1,948.00 + SEK3,138.52
SEK5,086.52
Equity Value per Share
(SEK)
= Total value / Shares Outstanding
= SEK5,086.52 / 65.20
SEK78.01
BATS-CHIXE:BIOTS Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BATS-CHIXE:BIOTS represents 0.99298x of OM:BIOT
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.99298x
Value per Share
(Listing Adjusted, SEK)
= Value per Share (SEK) x Listing Adjustment Factor
= SEK 78.01 x 0.99298
SEK77.46
Value per share (SEK) From above. SEK77.46
Current discount Discount to share price of SEK99.00
= -1 x (SEK99.00 - SEK77.46) / SEK77.46
-27.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Biotage is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Biotage's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Biotage's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BATS-CHIXE:BIOTS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in SEK SEK2.87
OM:BIOT Share Price ** OM (2020-03-30) in SEK SEK99.7
Europe Life Sciences Industry PE Ratio Median Figure of 18 Publicly-Listed Life Sciences Companies 48.4x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 747 Publicly-Listed Companies 12.45x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Biotage.

BATS-CHIXE:BIOTS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:BIOT Share Price ÷ EPS (both in SEK)

= 99.7 ÷ 2.87

34.79x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biotage is good value based on earnings compared to the Europe Life Sciences industry average.
  • Biotage is overvalued based on earnings compared to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Biotage's expected growth come at a high price?
Raw Data
BATS-CHIXE:BIOTS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 34.79x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
10.8%per year
Europe Life Sciences Industry PEG Ratio Median Figure of 15 Publicly-Listed Life Sciences Companies 2.05x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 526 Publicly-Listed Companies 0.95x

*Line of best fit is calculated by linear regression .

BATS-CHIXE:BIOTS PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 34.79x ÷ 10.8%

3.23x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biotage is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Biotage's assets?
Raw Data
BATS-CHIXE:BIOTS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in SEK SEK13.43
OM:BIOT Share Price * OM (2020-03-30) in SEK SEK99.7
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry PB Ratio Median Figure of 13 Publicly-Listed Life Sciences Companies 1.88x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,322 Publicly-Listed Companies 1.08x
BATS-CHIXE:BIOTS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:BIOT Share Price ÷ Book Value per Share (both in SEK)

= 99.7 ÷ 13.43

7.43x

* Primary Listing of Biotage.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biotage is overvalued based on assets compared to the GB Life Sciences industry average.
X
Value checks
We assess Biotage's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. Biotage has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Biotage expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
10.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Biotage expected to grow at an attractive rate?
  • Biotage's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • Biotage's earnings growth is positive but not above the United Kingdom of Great Britain and Northern Ireland market average.
  • Biotage's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
BATS-CHIXE:BIOTS Future Growth Rates Data Sources
Data Point Source Value (per year)
BATS-CHIXE:BIOTS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 10.8%
BATS-CHIXE:BIOTS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 10.5%
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 43.5%
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average -10.3%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 15.5%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 2.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BATS-CHIXE:BIOTS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BATS-CHIXE:BIOTS Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 1,508 313 256 1
2021-12-31 1,345 281 220 1
2020-12-31 1,211 235 196 1
2020-03-31
BATS-CHIXE:BIOTS Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2019-12-31 1,101 212 187
2019-09-30 1,047 187 196
2019-06-30 997 158 173
2019-03-31 951 139 170
2018-12-31 911 155 168
2018-09-30 865 170 175
2018-06-30 811 149 162
2018-03-31 771 168 148
2017-12-31 748 169 139
2017-09-30 738 145 122
2017-06-30 728 145 118
2017-03-31 694 131 105

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Biotage's earnings are expected to grow by 10.8% yearly, however this is not considered high growth (20% yearly).
  • Biotage's revenue is expected to grow by 10.5% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BATS-CHIXE:BIOTS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Biotage Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:BIOTS Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 3.93 3.93 3.93 1.00
2021-12-31 3.38 3.38 3.38 1.00
2020-12-31 3.01 3.01 3.01 1.00
2020-03-31
BATS-CHIXE:BIOTS Past Financials Data
Date (Data in SEK Millions) EPS *
2019-12-31 2.87
2019-09-30 3.01
2019-06-30 2.66
2019-03-31 2.63
2018-12-31 2.59
2018-09-30 2.70
2018-06-30 2.50
2018-03-31 2.29
2017-12-31 2.14
2017-09-30 1.88
2017-06-30 1.83
2017-03-31 1.63

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Biotage is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Biotage's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Biotage has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Biotage performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Biotage's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Biotage has delivered over 20% year on year earnings growth in the past 5 years.
  • Biotage's 1-year earnings growth is less than its 5-year average (11.5% vs 22.4%)
  • Biotage's earnings growth has exceeded the Europe Life Sciences industry average in the past year (11.5% vs 6.3%).
Earnings and Revenue History
Biotage's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Biotage Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:BIOTS Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 1,101.37 186.82 397.75 78.64
2019-09-30 1,047.35 195.65 372.97 77.34
2019-06-30 996.89 173.05 350.53 71.69
2019-03-31 950.87 170.29 337.06 69.54
2018-12-31 910.90 167.63 323.64 65.93
2018-09-30 865.21 174.95 306.92 59.47
2018-06-30 810.72 162.05 289.25 59.55
2018-03-31 770.97 148.31 272.14 56.29
2017-12-31 748.15 138.75 259.83 55.99
2017-09-30 738.41 121.59 261.54 52.91
2017-06-30 727.72 118.16 258.86 52.37
2017-03-31 694.27 105.22 252.66 51.87
2016-12-31 667.91 92.80 245.27 49.19
2016-09-30 657.31 96.02 233.75 51.87
2016-06-30 639.98 86.60 229.55 51.19
2016-03-31 625.23 77.52 223.94 48.60
2015-12-31 610.53 73.26 221.61 49.53
2015-09-30 579.74 82.69 213.87 47.12
2015-06-30 548.57 75.41 203.93 44.36
2015-03-31 520.84 75.15 195.71 42.83
2014-12-31 490.38 64.61 186.85 38.45
2014-09-30 474.27 52.94 181.57 34.60
2014-06-30 459.17 48.86 178.12 33.55
2014-03-31 455.13 46.38 178.27 33.86
2013-12-31 444.64 41.39 177.40 33.48
2013-09-30 436.94 36.52 178.22 33.39
2013-06-30 440.65 33.27 180.93 34.78

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Biotage has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Biotage used its assets more efficiently than the Europe Life Sciences industry average last year based on Return on Assets.
  • Biotage has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Biotage's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Biotage has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Biotage's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Biotage's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Biotage is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Biotage's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Biotage's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 5.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Biotage Company Filings, last reported 3 months ago.

BATS-CHIXE:BIOTS Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 875.50 109.55 185.87
2019-09-30 867.48 109.51 131.88
2019-06-30 782.06 149.94 108.08
2019-03-31 827.63 109.44 142.60
2018-12-31 702.18 109.40 177.02
2018-09-30 673.58 109.36 134.06
2018-06-30 632.40 109.33 95.84
2018-03-31 659.55 109.29 168.89
2017-12-31 608.61 0.00 174.26
2017-09-30 569.64 0.00 119.55
2017-06-30 545.68 0.00 101.64
2017-03-31 595.94 0.00 152.10
2016-12-31 563.24 0.00 128.62
2016-09-30 539.51 0.00 101.33
2016-06-30 510.27 0.00 99.57
2016-03-31 564.19 0.00 163.48
2015-12-31 546.66 0.00 134.89
2015-09-30 514.09 5.14 115.72
2015-06-30 496.10 5.00 90.31
2015-03-31 530.64 5.11 120.81
2014-12-31 516.15 5.04 100.05
2014-09-30 480.76 5.06 77.99
2014-06-30 464.73 5.09 66.91
2014-03-31 484.63 4.96 92.35
2013-12-31 476.77 5.74 90.77
2013-09-30 463.04 5.68 86.23
2013-06-30 468.93 5.90 88.63
  • Biotage's level of debt (12.5%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (1% vs 12.5% today).
  • Debt is well covered by operating cash flow (193.3%, greater than 20% of total debt).
  • Biotage earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess Biotage's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Biotage has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Biotage's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.6%
Current annual income from Biotage dividends. Estimated to be 2.04% next year.
If you bought SEK2,000 of Biotage shares you are expected to receive SEK32 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Biotage's pays a lower dividend yield than the bottom 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (2.69%).
  • Biotage's dividend is below the markets top 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (7.48%).
Upcoming dividend payment

Purchase Biotage before the 'Ex-dividend' to receive their next dividend payment.

Dividends are usually paid every 3 or 6 months, you can time your share purchase to take advantage of upcoming dividend payments.
Dividend payment calendar
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BATS-CHIXE:BIOTS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 12 Stocks 0.7%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 629 Stocks 6%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.4%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2.7%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 7.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BATS-CHIXE:BIOTS Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2022-12-31 2.30 1.00
2021-12-31 2.00 1.00
2020-12-31 1.80 1.00
2020-03-31
BATS-CHIXE:BIOTS Past Annualized Dividends Data
Date (Data in SEK) Dividend per share (annual) Avg. Yield (%)
2020-02-07 1.600 1.500
2019-03-25 1.500 1.328
2018-04-27 1.400 1.215
2017-04-28 1.250 1.810
2016-03-22 1.000 2.681
2016-02-11 1.000 3.906
2015-03-26 0.750 3.963
2014-03-26 0.600 4.986
2013-04-26 0.500 5.124
2012-04-27 0.400 4.944
2011-03-25 0.250 4.174
2010-04-30 0.200 2.833
2009-04-28 0.200 2.898

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been stable in the past 10 years.
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Biotage's earnings are paid to the shareholders as a dividend.
  • Dividends paid are covered by earnings (1.8x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be covered by earnings (1.7x coverage).
X
Income/ dividend checks
We assess Biotage's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Biotage afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Biotage has a total score of 4/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Biotage's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Tomas Blomquist
TENURE AS CEO 0.3 years
CEO Bio

Mr. Tomas Blomquist has been CEO and President of Biotage AB since November 6, 2019. Mr. Blomquist served as the Chief Operating Officer of Analyticon Biotechnologies AG. Mr. Blomquist served as Vice President EMEA Cardimetabolic at Abbott. Mr. Blomquist has experiences from Alere, Johnson & Johnson and Roche.

CEO Compensation
  • Insufficient data for Tomas to compare compensation growth.
  • Insufficient data for Tomas to establish whether their remuneration is reasonable compared to companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team

Tomas Blomquist

TITLE
CEO and President
TENURE
0.3 yrs

Lars Bäckman

TITLE
Former Chief Legal Officer
AGE
58

Anders Wikström

TITLE
Vice President of Operations
AGE
46
TENURE
9.8 yrs

Steve Jordan

TITLE
Chief Scientific Officer
AGE
66

Rikke Rytter

TITLE
Vice President Global Marketing
AGE
52

Cecilia Hållner

TITLE
Global Human Resources Director
AGE
47

Hans Johansson

TITLE
President of Biosystems
AGE
65

Scott Carr

TITLE
Vice President and Chief Executive Officer of North America

Lei Shi

TITLE
Chief Executive Officer of China
Board of Directors Tenure

Average tenure and age of the Biotage board of directors in years:

0.8
Average Tenure
53
Average Age
  • The average tenure for the Biotage board of directors is less than 3 years, this suggests a new board.
Board of Directors

Torben Jörgensen

TITLE
Chairman
COMPENSATION
SEK7M
AGE
67
TENURE
0.3 yrs

Thomas Eklund

TITLE
Director
COMPENSATION
SEK440K
AGE
52
TENURE
13.8 yrs

Karolina Lawitz

TITLE
Director
COMPENSATION
SEK257K
AGE
63
TENURE
7.8 yrs

Peter von Ehrenheim

TITLE
Director
COMPENSATION
SEK275K
AGE
64
TENURE
6.8 yrs

Love Amcoff

TITLE
Employee Representative Director
AGE
45

Annika Gärdlund

TITLE
Employee Representative Director
AGE
53
TENURE
1.4 yrs

Mark Bradley

TITLE
Director
TENURE
0.8 yrs

Åsa Hedin

TITLE
Director
AGE
57
TENURE
0.3 yrs

Dan Menasco

TITLE
Deputy Employee Representative Director
AGE
42
TENURE
0.3 yrs

Magnus Mörling

TITLE
Deputy Employee Representative Director
AGE
41
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • Biotage individual insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (SEK) Value (SEK)
11. Feb 20 Sell Erika Johnson Individual 11. Feb 20 11. Feb 20 -3,200 SEK125.90 SEK-402,880
30. Dec 19 Buy Love Amcoff Individual 30. Dec 19 30. Dec 19 1,000 SEK124.80 SEK124,800
X
Management checks
We assess Biotage's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Biotage has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Biotage AB (publ), a life science company, provides solutions, knowledge, and experience in the areas of organic and analytical chemistry, as well as for industrial applications in the United States, Europe, Japan, China, and internationally. It offers sample preparation solutions; horizon food and environmental products; microwave synthesis solutions; peptide synthesis and purification solutions; flash purification products; work-up products; evaporation and concentration solutions; and metal scavengers, reagents, scavengers, and custom resins. The company sells its products to pharmaceutical and biotechnical companies, contract research and manufacturing organizations, and academic institutions; and commercial, hospital/bio-analytical, and forensic laboratories, as well as laboratories within food and environmental analysis. The company is headquartered in Uppsala, Sweden.

Details
Name: Biotage AB
BIOTS
Exchange: BATS-CHIXE
Founded:
SEK6,454,976,616
65,201,784
Website: http://www.biotage.com
Address: Biotage AB
Box 8,
Uppsala,
Uppsala County, 751 03,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM BIOT Series A Common Stock OMX Nordic Exchange Stockholm SE SEK 30. Jun 2000
OTCPK BITG.F Series A Common Stock Pink Sheets LLC US USD 30. Jun 2000
DB PQX1 Series A Common Stock Deutsche Boerse AG DE EUR 30. Jun 2000
LSE 0GRP Series A Common Stock London Stock Exchange GB SEK 30. Jun 2000
BATS-CHIXE BIOTS Series A Common Stock BATS 'Chi-X Europe' GB SEK 30. Jun 2000
XTRA PQX SEK1 SER'A' XETRA Trading Platform DE EUR 08. Feb 2007
Number of employees
Current staff
Staff numbers
505
Biotage employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/31 19:52
End of day share price update: 2020/03/30 00:00
Last estimates confirmation: 2020/02/09
Last earnings filing: 2020/02/07
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.